Albert Luderer

Albert Luderer

Albert A. Luderer, Ph.D.

CEO & Board Member, Indi

Albert A. Luderer, Ph.D., has more than 30 years of successful leadership in medical diagnostics, laboratory medicine and therapeutic development. Prior to joining Indi, he served as President, CEO and Director of BioTrove Inc., a venture-backed Molecular Biological Tools company that was acquired by Life Technologies in December 2009. BioTrove was the 2009 recipient of Frost & Sullivan’s North American Drug Discovery Technologies and Growth Strategy Leadership of the Year Award and was recognized by Inc. 5000 as one of the fastest growing companies in North America. Dr. Luderer is the co-founder of Indi Molecular, which was spun-out from its parent company Indi (Integrated Diagnostics) in 2013. He also serves as Indi Molecular's CEO.

Dr. Luderer’s prior positions include: CEO of the venture-backed Therapeutics company Light Sciences Inc.; President and COO of bioMérieux, Inc.; Vice President of Technology and Business Development for Dianon Systems (now Lab Corp); Vice President of Technology Development and Support at Boehringer Mannheim (Now Roche) and; Head of Biomedical Research for Corning.

Dr. Luderer has developed and commercialized major In Vitro Diagnostic (IVD) systems including the global market leader for microbial detection and antibiotic susceptibility testing – Vitek®II, co-invented and established Standard of Care Diagnostics in cancer detection and has participated in the creation of one of the dominant global IVD companies – Siemens Diagnostics – through his participation in the negotiation and formation of the joint venture IVD firm Ciba Corning.

Dr. Luderer holds a Ph.D. from Rutgers University where he was an NSF pre doctoral fellow and performed post graduate work in immunology at Jefferson Medical College. He is an independent director of Agendia BV, BioNano Genomics and PrimeraDx. He is an advisor to Washington University’s Biomedical Engineering program.

 
You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue